These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35842959)

  • 1. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
    Menteş M; Karakuzulu BB; Uçar GB; Yandım C
    Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
    Kong D; Yamori T; Yamazaki K; Dan S
    Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
    Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
    Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.
    Gkeka P; Evangelidis T; Pavlaki M; Lazani V; Christoforidis S; Agianian B; Cournia Z
    PLoS Comput Biol; 2014 Oct; 10(10):e1003895. PubMed ID: 25340423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
    Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
    Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
    Hanan EJ; Braun MG; Heald RA; MacLeod C; Chan C; Clausen S; Edgar KA; Eigenbrot C; Elliott R; Endres N; Friedman LS; Gogol E; Gu XH; Thibodeau RH; Jackson PS; Kiefer JR; Knight JD; Nannini M; Narukulla R; Pace A; Pang J; Purkey HE; Salphati L; Sampath D; Schmidt S; Sideris S; Song K; Sujatha-Bhaskar S; Ultsch M; Wallweber H; Xin J; Yeap S; Young A; Zhong Y; Staben ST
    J Med Chem; 2022 Dec; 65(24):16589-16621. PubMed ID: 36455032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.
    Gkeka P; Papafotika A; Christoforidis S; Cournia Z
    J Phys Chem B; 2015 Jan; 119(3):1002-16. PubMed ID: 25299356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
    Sabbah DA; Vennerstrom JL; Zhong H
    J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.
    Leontiadou H; Galdadas I; Athanasiou C; Cournia Z
    Sci Rep; 2018 Oct; 8(1):15544. PubMed ID: 30341384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
    Ketcham JM; Harwood SJ; Aranda R; Aloiau AN; Bobek BM; Briere DM; Burns AC; Caddell Haatveit K; Calinisan A; Clarine J; Elliott A; Engstrom LD; Gunn RJ; Ivetac A; Jones B; Kuehler J; Lawson JD; Nguyen N; Parker C; Pearson KE; Rahbaek L; Saechao B; Wang X; Waters A; Waters L; Watkins AH; Olson P; Smith CR; Christensen JG; Marx MA
    J Med Chem; 2024 Mar; 67(6):4936-4949. PubMed ID: 38477582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.
    Thirumal Kumar D; George Priya Doss C
    J Biomol Struct Dyn; 2017 Sep; 35(12):2745-2757. PubMed ID: 27581627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.
    de Godoy BLV; Moschetta-Pinheiro MG; Chuffa LGA; Pondé NF; Reiter RJ; Colombo J; Zuccari DAPC
    Life Sci; 2023 Jul; 324():121708. PubMed ID: 37086897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer.
    R HC; Kumar S U; R G; Naayanan PJ; Sathiyarajeswaren P; Devi MSS; K SS; Doss C GP
    J Cell Biochem; 2023 Feb; 124(2):188-204. PubMed ID: 36563059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double
    Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
    Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
    Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
    Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
    Huang Q; Zhou Y; Wang B; Zhao Y; Zhang F; Ding B
    BMC Med Genomics; 2022 Jul; 15(1):146. PubMed ID: 35778737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer.
    Auf der Maur P; Trefny MP; Baumann Z; Vulin M; Correia AL; Diepenbruck M; Kramer N; Volkmann K; Preca BT; Ramos P; Leroy C; Eichlisberger T; Buczak K; Zilli F; Okamoto R; Rad R; Jensen MR; Fritsch C; Zippelius A; Stadler MB; Bentires-Alj M
    Cell Rep Med; 2023 Apr; 4(4):101002. PubMed ID: 37044095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.